NCT07685431 Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age
| NCT ID | NCT07685431 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kaohsiung Veterans General Hospital. |
| Condition | Female Infertility Due to Diminished Ovarian Reserve |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-06-11 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-06-11 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Female fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membranes, regenerates other antioxidants (vitamin C, vitamin E, glutathione, coenzyme Q10), and supports mitochondrial respiratory chain activity and ATP production. This prospective study will enroll 60 infertile women aged 35-45 years undergoing in vitro fertilization (IVF) treatment. Thirty participants will receive oral ALA 600 mg/day for two months before their IVF cycle, and thirty will proceed directly to IVF without supplementation. The study will compare oocyte and embryo quality, cumulus cell mitochondrial function and metabolic gene expression, and clinical pregnancy and live birth rates between the two groups.
Eligibility Criteria
Inclusion Criteria: * Age 35-45 years * BMI 18-35 kg/m² * Planning to undergo IVF treatment using own oocytes Exclusion Criteria: * Primary ovarian insufficiency * Azoospermia or severe male-factor infertility in the partner * Congenital uterine anomaly * Severe intrauterine adhesion * Known chromosomal anomaly in either partner * Malignancy * Recipient of donor oocytes * Known hypersensitivity/allergy to alpha-lipoic acid
Contact & Investigator
Kuan-Hao Tsui
STUDY DIRECTOR
Kaohsiung Veterans General Hospital.
Frequently Asked Questions
Who can join the NCT07685431 clinical trial?
This trial is open to female participants only, aged 35 Years or older, up to 45 Years, studying Female Infertility Due to Diminished Ovarian Reserve. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07685431 currently recruiting?
Yes, NCT07685431 is actively recruiting participants. Contact the research team at litelin1982@gmail.com for enrollment information.
Where is the NCT07685431 trial being conducted?
This trial is being conducted at Kaohsiung City, Taiwan.
Who is sponsoring the NCT07685431 clinical trial?
NCT07685431 is sponsored by Kaohsiung Veterans General Hospital.. The principal investigator is Kuan-Hao Tsui at Kaohsiung Veterans General Hospital.. The trial plans to enroll 60 participants.